Just ahead of the PDUFA date assigned to sarilumab, an end-of-the-week "oof" moment came for Regeneron Pharmaceuticals Inc. and Sanofi SA in the form of a complete response letter Friday regarding the BLA for their interleukin-6 antibody to treat adults with moderate to severe rheumatoid arthritis.